A one, two punch for liver cancer: anti-angiogenesis with a death receptor agonist.
Plastaras
John P
JP
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. plastaras@xrt.upenn.edu
Kozak
Kevin R
KR
D000818:Animals; D017209:Apoptosis; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D043169:Endostatins / Q000235:genetics / Q000378:metabolism*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010957:Plasmids / Q000235:genetics; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics / Q000378:metabolism*; D014162:Transfection; D016896:Treatment Outcome; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays
D043169:Endostatins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human